AF
ATXS

Allworth Financial’s Astria Therapeutics ATXS Stock Holding History

Allworth Financial’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-277
Closed -$1.44K – 4591
2025
Q1 		$1.44K Buy
+277
New +$1.94K ﹤0.01% 3332

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Allworth Financial's ATXS Position: Q2 2025 in Review

Allworth Financial sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 277 shares — an estimated $1.44K sold.

Allworth Financial first reported a position in ATXS in Q1 2025 and held it in 1 quarter. The position peaked at $1.44K in Q1 2025. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Allworth Financial reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Allworth Financial sold 277 Astria Therapeutics shares in Q2 2025, an estimated $1.44K.
  • Allworth Financial first reported a position in Astria Therapeutics in Q1 2025 and held it in 1 quarter.
  • Allworth Financial's Astria Therapeutics position peaked at $1.44K in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Allworth Financial's 13F filing for Q2 2025, filed 7 Aug 2025.